Ann: OIL September 2022 Quarterly Report and Appendix 4C, page-12

Well, if that's the case, even more reason to get some questions answered from the board on what the strategy has been for the last 3 years with the marketing and sales of five2. Or more to the point, why they even bothered setting up distributors with a device that would be extremely difficult to sell. Has the device been improved in the last couple of years? Why would they be training and doing marketing if the device as you say doesn't have FDA and limited research? Although I thought the device has been used by researchers over the last few years, so there must be quite a few papers with the research out there.

Anyway, I am sure the focus is on Invivage. As you say, ViewnVivo hopefully is the next FDA product after being modified for other cancerous areas.